-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics completes FDA dispute resolution meeting over LYTENAVA approval path

PUBT·04/21/2026 13:06:27
Listen to the news
Outlook Therapeutics completes FDA dispute resolution meeting over LYTENAVA approval path
  • Outlook Therapeutics completed Federal Dispute Resolution meeting with FDA Office of New Drugs on regulatory pathway for ONS-5010/LYTENAVA (bevacizumab-vikg).
  • Meeting followed Type A discussions tied to FDA Complete Response Letter dated Dec. 30, 2025 for BLA seeking approval in neovascular age-related macular degeneration.
  • Formal FDA feedback expected in May 2026, setting next steps toward potential U.S. approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210905PRIMZONEFULLFEED9693629) on April 21, 2026, and is solely responsible for the information contained therein.